Resistance to multiple chemotherapeutic agents remains a major obstacle in successful management of human malignancies. Recently a specific gene, termed mdr p-glycoprotein, has been demonstrated to be amplified and overexpressed in multidrug resistant cell lines. This gene which is a member of a multigene family has been shown to convey resistance to multiple drugs in vitro. This proposal is focused on the development of antibodies to specific epitopes of the polypeptides which make up the mdr p- glycoprotein family in the mouse and man. The characterization of these antibodies with respect to specificity for each family member and the interaction with specific functional sites on the polypeptide chain will provide essential information for studies on normal and neoplastic tissues. These antibodies will be essential in determining the distribution and expression of the mdr p- glycoprotein in normal tissues and clinically in neoplasms during chemotherapy. As the role of the mdr p-glycoprotein in the development of drug resistance is clarified then the potential application of appropriate monoclonal antibodies for the reversal of multidrug resistance in vivo will be considered. The specific goals of this project are: 1) generation of antibodies to the 3 members of the mdr p-glycoprotein gene family, 2) generate antibodies to specific domains within the different family members, 3) map the structure of the mdr p-glycoproteins 4) determine the tissue distrimdrn of each of the mdr p- glycoproteins, 5) determine the role each member of the gene family in the generation of drug resistance, 6) evaluate functional domains of the mdr p-glycoprotein family members, 7) screen human tumors with these antibodies to determine the role of this gene family in the clinical development of drug resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA048162-04
Application #
3192180
Study Section
Special Emphasis Panel (SRC (46))
Project Start
1988-09-01
Project End
1993-06-30
Budget Start
1991-07-11
Budget End
1992-06-30
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Zhang, X P; Ritke, M K; Yalowich, J C et al. (1994) P-glycoprotein mediates profound resistance to bisantrene. Oncol Res 6:291-301
Croop, J M (1993) P-glycoprotein structure and evolutionary homologies. Cytotechnology 12:1-32
Arceci, R J; Stieglitz, K; Bras, J et al. (1993) Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res 53:310-7
Piwnica-Worms, D; Chiu, M L; Budding, M et al. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53:977-84
Arceci, R J (1993) Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 81:2215-22
Mazzanti, R; Croop, J M; Gatmaitan, Z et al. (1992) Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res 4:359-65
Arceci, R J; Stieglitz, K; Bierer, B E (1992) Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80:1528-36
Buschman, E; Arceci, R J; Croop, J M et al. (1992) mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 267:18093-9
Gros, P; Dhir, R; Croop, J et al. (1991) A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci U S A 88:7289-93
Wu, C T; Budding, M; Griffin, M S et al. (1991) Isolation and characterization of Drosophila multidrug resistance gene homologs. Mol Cell Biol 11:3940-8

Showing the most recent 10 out of 12 publications